Literature DB >> 16597536

The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema.

Bram van Kooij1, Aniki Rothova, Philip de Vries.   

Abstract

Intravitreal triamcinolone acetonide (IVTA) injections are gaining in popularity and are regularly administered nowadays for various ocular diseases. This paper presents a literature review on the use, efficacy, and complications of IVTA application in non-infectious uveitis and inflammatory cystoid macular edema (CME). In addition, we describe the experiences of our own institute. IVTA applications brought about a quick improvement in vision in the majority of cases. Drawbacks included the temporary duration of the effect with the need for repeated injections which re-exposed patients to the risk of complications. The risk of bacterial endophthalmitis was 0.5% and was further influenced by the specific IVTA preparation. Based on the literature review, we chose ready-for-use IVTA injections prepared by our pharmacy department, in which 90% of the toxic additives were removed and the dispensed dose of triamcinolone acetonide was validated to diminish the risk of endophthalmitis. Elevated intraocular pressure (IOP) was seen in 30-43% of the eyes and cataract developed in 29% of the eyes of patients, who were usually of advanced age. In conclusion, the rapid effect of IVTA might be of value in severe presentations of non-infectious uveitis and CME and might shorten the time interval needed for the improvement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597536     DOI: 10.1080/09273940500545684

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  18 in total

1.  Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.

Authors:  Viral Tamboli; Gyan P Mishra; Ashim K Mitra
Journal:  Colloid Polym Sci       Date:  2013-05-01       Impact factor: 1.931

2.  [Therapy of intermediate uveitis].

Authors:  D Doycheva; C Deuter; M Zierhut
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

3.  Intravitreal Injection of Normal Saline Induces Retinal Degeneration in the C57BL/6J Mouse.

Authors:  Jose R Hombrebueno; Chang Luo; Linda Guo; Mei Chen; Heping Xu
Journal:  Transl Vis Sci Technol       Date:  2014-03-27       Impact factor: 3.283

4.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion.

Authors:  E Moisseiev; M Goldstein; M Waisbourd; A Barak; A Loewenstein
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

6.  Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.

Authors:  Michal Schaap-Fogler; Radgonde Amer; Ronit Friling; Ethan Priel; Michal Kramer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-12-24       Impact factor: 3.117

7.  Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.

Authors:  Ji Hun Song; Young Taek Hong; Oh Woong Kwon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-27       Impact factor: 3.117

8.  Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.

Authors:  Rushmia Karim; Evripidis Sykakis; Susan Lightman; Samantha Fraser-Bell
Journal:  Clin Ophthalmol       Date:  2013-06-11

9.  Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant.

Authors:  Jane S Myung; Grant D Aaker; Szilárd Kiss
Journal:  Clin Ophthalmol       Date:  2010-12-06

10.  Dexamethasone intravitreal implant for the treatment of noninfectious uveitis.

Authors:  Rebecca S Hunter; Ann-Marie Lobo
Journal:  Clin Ophthalmol       Date:  2011-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.